About Forma Therapeutics
Forma Therapeutics is a company based in Watertown (United States) founded in 2007 was acquired by Novo Nordisk in September 2022. Forma Therapeutics has raised $417.55 million across 8 funding rounds from investors including Novartis, Novo Nordisk and Janus Henderson Investors. The company has 165 employees. Forma Therapeutics offers products and services including Ozempic. Forma Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Denali Therapeutics, C4 Therapeutics, Erasca and Revolution Medicines, among others.
- Headquarter Watertown, United States
- Employees 165
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website formatherapeutics.com
- Social LinkedIn X Facebook
- Acquired by Novo Nordisk (Sep 2022)
- Legal Name Novo Nordisk A/S
- Total Equity Funding$417.55M (USD)
in 8 rounds
- Latest Funding Round$100M (USD), Series D
Dec 2019
- InvestorsNovartis
& 10 more
- Employee Count165
- Acquired byNovo Nordisk
(Sep 2022)
Products & Services of Forma Therapeutics
Forma Therapeutics offers a comprehensive portfolio of products and services, including Ozempic.
Medication for managing type 2 diabetes and improving patient outcomes.
Funding Insights of Forma Therapeutics
Forma Therapeutics has successfully raised a total of $417.55M across 8 strategic funding rounds. The most recent funding activity was a Series D round of $100 million completed in December 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $417.55M
- Total Rounds 8
- Last Round Series D — $100M
- First Round $4M
(Mar 2008)
- Investors Count 10
All 8 funding rounds of Forma Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2019 | $100M | Series D | – | RA Capital Management | |
| Feb 2017 | – | Grant | – | – | |
| Apr 2014 | $225M | Series D | – | Celgene | – |
| Sep 2012 | $10M | Series C | – | – | – |
| Dec 2011 | $50.05M | Series C | – | – | – |
| Dec 2009 | $3M | Series B | – | – | – |
| Dec 2009 | $25.5M | Series B | – | Lilly Ventures | |
| Mar 2008 | $4M | Series A | – | Novartis Venture Fund | – |
11 investors in total: 11 institutional.
Investors in Forma Therapeutics
Forma Therapeutics has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Novartis, Novo Nordisk and Janus Henderson Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital funding is provided by Samsara BioCapital in California. | – | samsaracap.com | Palo Alto, United States | |
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Early-stage life sciences investments are targeted in the healthcare sector. | – | lillyventures.com | Indianapolis, United States | |
Government-backed investments are directed toward healthcare, fintech, and various sectors. | – | edbi.com | Singapore, Singapore | |
Investments are made in innovative life science companies globally. | – | nvfund.com | Basel, Switzerland | |
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
Diversified investment management services are provided to institutional clients. | – | wellington.com | Boston, United States | |
Research for Parkinson's disease is funded by the foundation. | 2000 | michaeljfox.org | New York, United States | |
Therapies for cancer and inflammatory diseases are developed. | 1986 | celgene.com | Summit, United States | |
R&D focused on manufacturing of drugs for multiple therapeutic areas | 1996 | novartis.com | Basel, Switzerland |
Investor details for Forma Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Forma Therapeutics
15 people are tracked at Forma Therapeutics (6 in leadership, 7 in board & advisors, 2 in team); the tracked headcount is 165.
| Name | Role | Group |
|---|---|---|
Frank Lee | CEO | Leadership |
Katy Burnett | VP, Finance | Leadership |
Shihara Azard | Director, CMC Operations PM | Leadership |
Jim O'Connell | Executive Director Of Operations | Leadership |
Irena Webster | VP, Development Operations | Leadership |
Mark Chamberlin | Corporate Counsel-executive Director | Leadership |
Marsha Fanucci | Board Member | Board & advisors |
Peter Kolchinsky | Board Member | Board & advisors |
Arturo Molina | Board Member | Board & advisors |
Thomas G. Wiggans | Board Member | Board & advisors |
Timothy P. Clackson | Board Member | Board & advisors |
Tim Clackson | Board Member | Board & advisors |
Wayne A. I. Frederick | Board Member | Board & advisors |
Kirwyn Sutherland | Senior Clinical Data Manager | Team |
Tina Atkinson | Principle Research Associate | Team |
Complete people profiles for Forma Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Forma Therapeutics
5 dated milestones of Forma Therapeutics across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Forma Therapeutics is founded.
- Funding First funding round of $4.0M.
- Funding Latest funding round, Series D, of $100.0M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Novo Nordisk.
Competitors of Forma Therapeutics
Forma Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Denali Therapeutics, C4 Therapeutics, Erasca and Revolution Medicines, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. |
Detailed competitors of Forma Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Forma Therapeutics
Websites that share an audience with Forma Therapeutics (formatherapeutics.com).
Websites whose visitors overlap most with Forma Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| sorrentotherapeutics.com | 100% | 1.4K | #12,489,091 | View details | |
| scholarrock.com | 91% | 11.7K | #1,646,973 | View details | |
| momentapharma.com | 89% | – | #11,284,544 | View details | |
foundationone.com | foundationone.com | 57% | – | – | – |
Latest news on Forma Therapeutics
Complete news archive for Forma Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Forma Therapeutics
10 companies that operate in the same segment as Forma Therapeutics (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Forma Therapeutics
Forma Therapeutics was founded in 2007 and raised its 1st funding round 1 year after it was founded.
Forma Therapeutics is headquartered in Watertown, United States.
Frank Lee is the current CEO of Forma Therapeutics.
Forma Therapeutics is a funded company, having raised a total of $417.55M across 8 funding rounds to date. The company's 1st funding round was a Series A of $4M, raised on Mar 2008.
Forma Therapeutics has 165 employees.
Forma Therapeutics was founded in 2007 and is based in Watertown, United States. Operations focus on biotechnology, where drug discovery engines are utilized to screen and apply structure-based methods across targets in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. Lead candidates such as FT-4202 for sickle cell disease, FT-7051 for acute myeloid leukemia, and olutasidenib for glioma are advanced through development pipelines.
Forma Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Forma Therapeutics offers Ozempic.
Forma Therapeutics has 11 investors. Key investors include Novartis, Novo Nordisk, Janus Henderson Investors, RA Capital, and Celgene.
Forma Therapeutics operates through Novo Nordisk A/S.
Yes. Forma Therapeutics was acquired by Novo Nordisk in September 2022.